PE20240890A1 - Moduladores de los receptores acoplados a proteinas g - Google Patents
Moduladores de los receptores acoplados a proteinas gInfo
- Publication number
- PE20240890A1 PE20240890A1 PE2023003051A PE2023003051A PE20240890A1 PE 20240890 A1 PE20240890 A1 PE 20240890A1 PE 2023003051 A PE2023003051 A PE 2023003051A PE 2023003051 A PE2023003051 A PE 2023003051A PE 20240890 A1 PE20240890 A1 PE 20240890A1
- Authority
- PE
- Peru
- Prior art keywords
- formula
- gipr
- glp
- pharmaceutically acceptable
- acceptable salt
- Prior art date
Links
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 title 1
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 title 1
- 102100039997 Gastric inhibitory polypeptide receptor Human genes 0.000 abstract 3
- 108010086246 Glucagon-Like Peptide-1 Receptor Proteins 0.000 abstract 3
- 102100032882 Glucagon-like peptide 1 receptor Human genes 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 3
- 101000886866 Homo sapiens Gastric inhibitory polypeptide receptor Proteins 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 230000008484 agonism Effects 0.000 abstract 1
- 230000001270 agonistic effect Effects 0.000 abstract 1
- 230000008485 antagonism Effects 0.000 abstract 1
- 230000009286 beneficial effect Effects 0.000 abstract 1
- 150000005829 chemical entities Chemical class 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 108010036598 gastric inhibitory polypeptide receptor Proteins 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Toxicology (AREA)
- Public Health (AREA)
- Zoology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Obesity (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Holo Graphy (AREA)
- Gyroscopes (AREA)
- Amplifiers (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
La presente invencion se refiere a un compuesto o una sal farmaceuticamente aceptable que modulan (agonizan o agonizan parcialmente o antagonizan) el receptor del peptido similar al glucagon tipo 1 ("GLP-1R") y/o el receptor del polipeptido inhibidor gastrico ("GIPR"). Asimismo, la invencion presenta composiciones, asi como otros metodos de uso y fabricacion de entidades quimicas. Los compuestos quimicos son utiles para tratar una enfermedad, trastorno o afeccion en donde la modulacion (agonismo, el agonismo parcial o el antagonismo) de las actividades de GLP-1R y/o de GIPR es beneficiosa para el tratamiento de diabetes, NASH, obesidad, entre otros. En particular, la presente invencion hace referencia a un compuesto de la Formula (I) o una sal farmaceuticamente aceptable del mismo, en el que Q es O o S; R es formula (A), formula (B) o formula (C); cada uno de R1 y R2 se selecciona de manera independiente del grupo que consiste en H y alquilo C1-3; a1 es 0, 1, 2, 3 o 4; R2' es (a); -N(R4)-W tiene la Formula WD: GT(Xaa3)(Xaa4)SD(Xaa7)SI(Xaa10)LD(Xaa13)(Xaa14)A(Xaa16)(Xaa17)(X aa18)F(Xaa20)(Xaa21)(Xaa22)L(Xaa24)(Xaa25)GGPSSGAPPPS(Xaa37)-R6 (SEQ ID NO: 4).
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163188342P | 2021-05-13 | 2021-05-13 | |
| PCT/US2022/029305 WO2022241287A2 (en) | 2021-05-13 | 2022-05-13 | Modulators of g-protein coupled receptors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20240890A1 true PE20240890A1 (es) | 2024-04-24 |
Family
ID=82019613
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2023003051A PE20240890A1 (es) | 2021-05-13 | 2022-05-13 | Moduladores de los receptores acoplados a proteinas g |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US20230151074A1 (es) |
| EP (1) | EP4337682A2 (es) |
| JP (1) | JP2024517942A (es) |
| KR (1) | KR20240007251A (es) |
| CN (1) | CN117980325A (es) |
| AU (1) | AU2022272251A1 (es) |
| BR (1) | BR112023023559A2 (es) |
| CA (1) | CA3220005A1 (es) |
| CL (1) | CL2023003369A1 (es) |
| CO (1) | CO2023015805A2 (es) |
| CR (1) | CR20230530A (es) |
| DO (1) | DOP2023000247A (es) |
| EC (1) | ECSP23093673A (es) |
| IL (1) | IL308392A (es) |
| PE (1) | PE20240890A1 (es) |
| TW (1) | TW202313666A (es) |
| WO (1) | WO2022241287A2 (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20240007251A (ko) * | 2021-05-13 | 2024-01-16 | 카모트 테라퓨틱스, 인크. | G-단백질 결합 수용체의 조절제 |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0862562B1 (en) | 1995-09-13 | 2001-07-04 | Takeda Chemical Industries, Ltd. | Benzoxazepine compounds, their production and use as lipid lowering agents |
| AR035016A1 (es) | 1999-08-25 | 2004-04-14 | Takeda Chemical Industries Ltd | Composicion de azol promotor de produccion/secrecion de neurotrofina, compuesto prodroga del mismo, composicion farmaceutica que lo comprende y uso del mismo para preparar esta ultima. |
| WO2002006234A1 (fr) | 2000-07-17 | 2002-01-24 | Takeda Chemical Industries, Ltd. | Derives de sulfonate, procede de production et utilisation de ces derives |
| AU2003278600A1 (en) | 2002-11-01 | 2004-05-25 | Takeda Pharmaceutical Company Limited | Agent for preventing or treating neuropathy |
| AU2003277576A1 (en) | 2002-11-08 | 2004-06-07 | Takeda Pharmaceutical Company Limited | Receptor function controlling agent |
| AU2003284596A1 (en) | 2002-11-22 | 2004-06-18 | Takeda Pharmaceutical Company Limited | Imidazole derivative, process for producing the same, and use |
| CA2527691C (en) | 2003-05-30 | 2013-01-22 | Takeda Pharmaceutical Company Limited | Condensed ring compound |
| US7534887B2 (en) | 2003-09-30 | 2009-05-19 | Takeda Pharmaceutical Company Limited | Thiazoline derivative and use of the same |
| US7820673B2 (en) | 2003-12-17 | 2010-10-26 | Takeda Pharmaceutical Company Limited | Urea derivative, process for producing the same, and use |
| TW200523247A (en) | 2003-12-25 | 2005-07-16 | Takeda Pharmaceutical | 3-(4-benzyloxyphenyl) propanoic acid derivatives |
| WO2005063725A1 (ja) | 2003-12-26 | 2005-07-14 | Takeda Pharmaceutical Company Limited | フェニルプロパン酸誘導体 |
| US7786165B2 (en) | 2004-03-15 | 2010-08-31 | Takeda Pharmaceutical Company Limited | Aminophenylpropanoic acid derivative |
| JP4859665B2 (ja) | 2004-03-30 | 2012-01-25 | 武田薬品工業株式会社 | アルコキシフェニルプロパン酸誘導体 |
| TWI396686B (zh) | 2004-05-21 | 2013-05-21 | Takeda Pharmaceutical | 環狀醯胺衍生物、以及其製品和用法 |
| US20060275288A1 (en) | 2005-01-20 | 2006-12-07 | Grihalde Nelson D | GLP-1 receptor agonist and allosteric modulator monoclonal antibodies and uses thereof |
| US8957070B2 (en) | 2005-04-20 | 2015-02-17 | Takeda Pharmaceutical Company Limited | Glucokinase activator compounds, methods of activating glucokinase and methods of treating diabetes and obesity |
| EP1911738A4 (en) | 2005-07-29 | 2009-12-16 | Takeda Pharmaceutical | PHENOXYALKANSÄUREVERBINDUNG |
| US8153694B2 (en) | 2005-07-29 | 2012-04-10 | Takeda Pharmaceutical Company Limited | Cyclopropanecarboxylic acid compound |
| US20080009530A1 (en) | 2005-08-10 | 2008-01-10 | Hidenori Abe | Therapeutic Agent for Diabetes |
| JP2007063225A (ja) | 2005-09-01 | 2007-03-15 | Takeda Chem Ind Ltd | イミダゾピリジン化合物 |
| EP2743268A3 (en) | 2006-06-27 | 2014-10-08 | Takeda Pharmaceutical Company Limited | Fused cyclic compounds as GPR40 receptor modulators |
| EP2298772A1 (en) | 2006-10-18 | 2011-03-23 | Takeda Pharmaceutical Company Limited | Fused heterocyclic compounds |
| US7652133B2 (en) | 2006-10-19 | 2010-01-26 | Takeda Pharmaceutical Company Limited | Indole compound |
| JPWO2008093639A1 (ja) | 2007-01-29 | 2010-05-20 | 武田薬品工業株式会社 | ピラゾール化合物 |
| WO2008099794A1 (en) | 2007-02-09 | 2008-08-21 | Takeda Pharmaceutical Company Limited | Fused ring compounds as partial agonists of ppar-gamma |
| EP2149550A4 (en) | 2007-04-27 | 2010-08-11 | Takeda Pharmaceutical | HETEROCYCLIC COMPOUND WITH FIVE NITROGEN CHAINS |
| EP2157859A4 (en) | 2007-06-19 | 2011-01-12 | Takeda Pharmaceutical | INDAZOL COMPOUNDS FOR THE ACTIVATION OF GLUCCOKINASE |
| EP2952202B1 (en) | 2008-06-17 | 2017-10-18 | Indiana University Research and Technology Corporation | Gip-based mixed agonists for treatment of metabolic disorders and obesity |
| US20120148586A1 (en) | 2009-08-27 | 2012-06-14 | Joyce Ching Tsu Chou | Glucagon-like protein-1 receptor (glp-1r) agonists for treating autoimmune disorders |
| US20120021979A1 (en) | 2010-06-24 | 2012-01-26 | Vanderbilt University | GLP-1 receptor modulation of addiction, neuropsychiatric disorders and erectile dysfunction |
| WO2016131893A1 (en) | 2015-02-18 | 2016-08-25 | Medimmune Limited | Incretin fusion polypeptides |
| IL277495B1 (en) * | 2018-03-23 | 2024-04-01 | Carmot Therapeutics Inc | Modulators of protein-coupled receptors - G |
| KR20240007251A (ko) * | 2021-05-13 | 2024-01-16 | 카모트 테라퓨틱스, 인크. | G-단백질 결합 수용체의 조절제 |
-
2022
- 2022-05-13 KR KR1020237042878A patent/KR20240007251A/ko unknown
- 2022-05-13 BR BR112023023559A patent/BR112023023559A2/pt unknown
- 2022-05-13 WO PCT/US2022/029305 patent/WO2022241287A2/en active Application Filing
- 2022-05-13 JP JP2023569936A patent/JP2024517942A/ja active Pending
- 2022-05-13 US US17/744,540 patent/US20230151074A1/en active Pending
- 2022-05-13 TW TW111118138A patent/TW202313666A/zh unknown
- 2022-05-13 CN CN202280048710.4A patent/CN117980325A/zh active Pending
- 2022-05-13 IL IL308392A patent/IL308392A/en unknown
- 2022-05-13 AU AU2022272251A patent/AU2022272251A1/en active Pending
- 2022-05-13 CR CR20230530A patent/CR20230530A/es unknown
- 2022-05-13 PE PE2023003051A patent/PE20240890A1/es unknown
- 2022-05-13 EP EP22729907.0A patent/EP4337682A2/en active Pending
- 2022-05-13 CA CA3220005A patent/CA3220005A1/en active Pending
-
2023
- 2023-11-09 DO DO2023000247A patent/DOP2023000247A/es unknown
- 2023-11-10 CL CL2023003369A patent/CL2023003369A1/es unknown
- 2023-11-21 CO CONC2023/0015805A patent/CO2023015805A2/es unknown
- 2023-12-13 EC ECSENADI202393673A patent/ECSP23093673A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN117980325A (zh) | 2024-05-03 |
| CR20230530A (es) | 2024-02-19 |
| CO2023015805A2 (es) | 2023-12-11 |
| ECSP23093673A (es) | 2024-01-31 |
| IL308392A (en) | 2024-01-01 |
| WO2022241287A2 (en) | 2022-11-17 |
| US20230151074A1 (en) | 2023-05-18 |
| CL2023003369A1 (es) | 2024-05-17 |
| CA3220005A1 (en) | 2022-11-17 |
| KR20240007251A (ko) | 2024-01-16 |
| AU2022272251A1 (en) | 2023-11-16 |
| TW202313666A (zh) | 2023-04-01 |
| JP2024517942A (ja) | 2024-04-23 |
| BR112023023559A2 (pt) | 2024-02-06 |
| EP4337682A2 (en) | 2024-03-20 |
| WO2022241287A3 (en) | 2022-12-29 |
| DOP2023000247A (es) | 2024-03-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20240890A1 (es) | Moduladores de los receptores acoplados a proteinas g | |
| AR031701A1 (es) | COMPUESTOS ANA LOGOS DEL (GLP-1)-PEPTIDO-1 ANALOGO DEL GLUCAGoN, METODO PARA ESTIMULAR LOS RECEPTORES GLP-1 UTILIZANDO DICHOS COMPUESTOS Y USO DE DICHOS COMPUESTOS EN LA PREPARACION DE MEDICAMENTOS PARA ESTIMULAR LA SECRECION DE INSULINA | |
| PE20070498A1 (es) | Compuestos derivados de indoles de acilo como antagonistas del receptor de glucagon | |
| UY26974A1 (es) | Agonistas del receptor beta3 adrenérgico y usos de los mismos | |
| Retnakaran et al. | Ecdysone agonists: mechanism and importance in controlling insect pests of agriculture and forestry | |
| PE20231181A1 (es) | Agonistas del glp-1 heterociclicos | |
| PE20221040A1 (es) | Compuestos moduladores de glp-1r | |
| PE20120578A1 (es) | Agonistas y antagonistas del receptor de s1p5, y metodos de uso de los mismos | |
| PE20091222A1 (es) | Bifenilo sustituidos como moduladores del receptor gpra40 | |
| PE20080075A1 (es) | Compuestos fenil amido heterociclicos condensados | |
| JP2008500281A5 (es) | ||
| ES2632265T3 (es) | Azinas sustituidas como plaguicidas | |
| PE20070519A1 (es) | Derivados de fenilmorfolina y feniltiomorfolina como agonistas de adrenoreceptores alfa 2c | |
| PE20220938A1 (es) | Compuestos agonistas de gipr | |
| AR074965A1 (es) | Compuestos antidiabeticos heterociclicos puenteados y fusionados | |
| IL106324A (en) | Transformed pyrimidine compounds, their preparation and use as pesticides | |
| UY31496A1 (es) | Agonistas novedosos de los receptores de glucocorticoides | |
| CO6280539A2 (es) | Agonistas mezclados, basados en gip para el tratamiento de trastornos metabolicos y obesidad | |
| PE20060237A1 (es) | Derivados de fenol y tiofenol 3- o 4-monosustituidos como ligandos de h3 | |
| PE20121316A1 (es) | Composicion farmaceutica que comprende un agonista de glp-1 y metionina | |
| PE20121046A1 (es) | Terapia de combinacion para el tratamiento de la diabetes | |
| AR064334A1 (es) | Compuestos peptidicos y sus efectos sobre la alimentacion | |
| PE20061014A1 (es) | Clorhidrato de lercanidipina amorfo | |
| PE20061220A1 (es) | Bifenilsulfonamidas y proceso para su preparacion | |
| PE20010118A1 (es) | Compuestos imidazoles sustituidos como antagonistas de neuropeptido y |